Vir Biotechnology, INC 8-K filings
NASDAQ
8-K: Vir Biotechnology Terminates Influenza Collaboration with GSK, Reports Q4 and Full Year 2023 Results
Vir Biotechnology ended its influenza program collaboration with GSK, while also reporting its fourth quarter and full year 2023 financial results, including a significant decrease in revenue compared to 2022.
NASDAQ
Vir Biotechnology's Chief Medical Officer, Phil Pang, M.D., Ph.D., will depart at the end of March 2024 to spend more time with his family.